Type 2 Diabetes Archives

Med Ad News 2022 Marketer on the Rise: Allison Garrity

Annual Reports, April 2022, AstraZeneca, Blockbusters, Chronic Kidney Disease, Heart Failure, Issue Archives, Manny Awards, Marketing & Advertising, Med Ad News, Therapeutics, Type 2 Diabetes

When you have a brand with as much promise as Farxiga, you need someone at the helm with the drive and vision to help it reach its full potential. And that person is senior director of marketing for Farxiga, Allison Garrity. When Garrity joined the Farxiga team, the established AstraZeneca brand already had a strong legacy in type 2 diabetes (T2D), but momentum had stalled, teams needed to be rebuilt, and – the biggest challenge of all – Farxiga had to revolutionize care again, this time with indications in heart failure (HF) and chronic kidney disease (CKD).

May 2, 2022/by Andrew Humphreys

Risk of type 2 diabetes rises after COVID; organ transplant from donors who had COVID likely safe

Coronavirus Disease (COVID-19) Pandemic, COVID-19 Severe Complications, COVID-19 Studies, JAMA Psychiatry, Medical Journals, Neuropsychiatric Diseases, Organ Transplantation, R&D, Reuters, The Lancet Diabetes & Endocrinology, Type 2 Diabetes, U.S. Department of Veterans Affairs

People may be at increased risk for developing diabetes for up to a year after a diagnosis of COVID-19, according to two studies. Additionally, organ donation from dying donors with current or previous COVID-19 infection is likely safe, transplant teams from the United States and Italy will report at the April 2022 European Congress of Clinical Microbiology & Infectious Diseases meeting.

March 23, 2022/by Reuters Health

Studies Suggest Links Between COVID-19 and Diabetes, Pregnancy Risks and Dementia

Clinical Trials, Coronavirus Disease 2019 (COVID-19), COVID-19 Studies, Dementia, Diabetes, Heart Problems, JAMA Internal Medicine, Nature Medicine, Neurological Conditions, Pregnancies, R&D, The Lancet Diabetes & Endocrinology, Type 2 Diabetes, University of Iowa, University of Rochester Medical Center

The most obvious risks from COVID-19 are hospitalization and death. But study after study shows the disease comes with an increased risk of a number of health problems, including diabetes.

March 22, 2022/by BioSpace

Research Roundup: New Insights into Alzheimer’s Progression and More

3D, Alzheimer’s Disease, Blood Vessels, Cambridge University, Clinical Trials, COVID-19 Antibodies, Data, Elderly, Medical Journals, Nerve Cells, R&D, Retina, Science Advances, Type 2 Diabetes

Researchers with the University of Cambridge for the first time leveraged human data to quantify the speed of various processes in the brain that lead to Alzheimer’s disease.

November 5, 2021/by BioSpace

AREA 23 and Hip Hop Public Health Launch “Lil Sugar,” Exposing the Many Hidden Forms of Sugar in Food Products

Campaign Launches, Campaigns, Children, Data, Food, Health Education, Healthcare Communications Agencies, Healthcare Communications Networks, Marketing & Advertising, Nonprofit, Obesity, Sugar, Type 2 Diabetes

AREA 23 (an IPG Health company) launched the multi-platform campaign “Lil Sugar” in collaboration with global non-profit organization Hip Hop Public Health to raise awareness about the hidden sugars in many foods.

October 5, 2021/by Andrew Humphreys

Research Roundup: Underlying Conditions, Covid-19 Severity and More

Alzheimer's, Cells, COVID-19 Studies, Health Outcomes, Ireland, Mount Sinai, Neuron, Prediabetes, R&D, Salk Institute, The Lancet Regional Health – Europe, Type 2 Diabetes, Washington University School of Medicine in St. Louis

In a roundup review of scientific studies recently published, a study out of RCSI University of Medicine and Health Sciences and the HSE Health Protection Surveillance Centre (HPSC) in Ireland further defined the association between comorbidities and poor outcomes with Covid-19.

April 30, 2021/by Andrew Humphreys

AstraZeneca wins two approval recommendations from EU agency

Chronic Obstructive Pulmonary Disease (COPD), Committee for Medicinal Products for Human Use, Diabetes, European Commission, European Medicines Agency, Heart Failure, Lung Disorders, Recommended For Approval, Therapeutics, Type 2 Diabetes

The European medicines watchdog recommended approving AstraZeneca’s treatments for a form of heart failure and a lung disorder, the British drugmaker said.

October 19, 2020/by Andrew Humphreys

AstraZeneca diabetes drug improves survival in kidney disease patients study shows

Blockbusters, Chronic Kidney Disease, Clinical Trials, Diabetes, Heart, Kidney Functioning, Kidneys, Placebo, R&D, SGLT2 Inhibitors, Therapeutics, Type 2 Diabetes

AstraZeneca’s Farxiga improved survival chances for patients suffering from kidney disease, underscoring the medicine’s role outside the drug’s established field of diabetes.

August 30, 2020/by Andrew Humphreys

DTC Special Feature 2020: It’s alive!

April 2020, Blockbusters, DTC, DTC, Healthcare Communications Agencies, Healthcare Communications Networks, Issue Archives, Marketing & Advertising, Med Ad News, Special Features, TV Commercials, Type 2 Diabetes

For all the digital and interactive tools that keep popping up, television remains the DTC marketer’s old reliable.

April 27, 2020/by Joshua Slatko

European drug panel recommends approving Novo Nordisk’s new diabetes pill

Blockbusters, Committee for Medicinal Products for Human Use (CHMP), Diabetes, European Commission, European Medicines Agency (EMA), FDA/Regulatory, First-of-its kind, Glucagon-Like Peptide-1 (GLP-1) Analogs, Injectables, Recommended For Approval, Type 2 Diabetes

A panel of the European medicines regulator recommended approving Novo Nordisk’s new diabetes pill Rybelsus, further boosting prospects for the Danish drugmaker with the company’s first-of-a-kind, non-injectable treatment.

January 31, 2020/by Reuters Health